Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard L Parnes

Showing results (41-50 of 110) with videos related to

Pageof 11
Sort By:
Urologic Oncology|May 5, 2010
BCAN Think Tank session 3: Prevention of bladder cancerSeth P Lerner, H Barton Grossman, Edward M Messing, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 23, 2017
A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue BiomarkersJason R Gee, Daniel R Saltzstein, KyungMann Kim, et al.
The Journal of Urology|April 20, 2010
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancerWilliam D Figg, Sukyung Woo, Wenhui Zhu, et al.
The Journal of Urology|February 13, 2014
Statin drug use is not associated with prostate cancer risk in men who are regularly screenedElizabeth A Platz, Catherine M Tangen, Phyllis J Goodman, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 1, 2015
Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention TrialSarah H Nash, Jeannette M Schenk, Alan R Kristal, et al.
The Journal of Urology|September 11, 2016
Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate CancerThomas P Frye, Arvin K George, Amichai Kilchevsky, et al.
The Lancet. Oncology|February 14, 2012
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A Madan, Mahsa Mohebtash, Philip M Arlen, et al.
Journal of the National Cancer Institute|July 12, 2013
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trialTheodore M Brasky, Amy K Darke, Xiaoling Song, et al.
The Prostate|June 8, 2020
The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention TrialSusan Chadid, John R Barber, William G Nelson, et al.
The New England Journal of Medicine|May 28, 2004
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliterIan M Thompson, Donna K Pauler, Phyllis J Goodman, et al.
Pageof 11

Showing results (41-50 of 110) with videos related to

Sort By:
Pageof 11
Urologic Oncology|May 5, 2010
BCAN Think Tank session 3: Prevention of bladder cancerSeth P Lerner, H Barton Grossman, Edward M Messing, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 23, 2017
A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue BiomarkersJason R Gee, Daniel R Saltzstein, KyungMann Kim, et al.
The Journal of Urology|April 20, 2010
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancerWilliam D Figg, Sukyung Woo, Wenhui Zhu, et al.
The Journal of Urology|February 13, 2014
Statin drug use is not associated with prostate cancer risk in men who are regularly screenedElizabeth A Platz, Catherine M Tangen, Phyllis J Goodman, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 1, 2015
Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention TrialSarah H Nash, Jeannette M Schenk, Alan R Kristal, et al.
The Journal of Urology|September 11, 2016
Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate CancerThomas P Frye, Arvin K George, Amichai Kilchevsky, et al.
The Lancet. Oncology|February 14, 2012
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A Madan, Mahsa Mohebtash, Philip M Arlen, et al.
Journal of the National Cancer Institute|July 12, 2013
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trialTheodore M Brasky, Amy K Darke, Xiaoling Song, et al.
The Prostate|June 8, 2020
The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention TrialSusan Chadid, John R Barber, William G Nelson, et al.
The New England Journal of Medicine|May 28, 2004
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliterIan M Thompson, Donna K Pauler, Phyllis J Goodman, et al.
Pageof 11